Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Seattle Genetics, Inc.    SGEN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Seattle Genetics, Inc. : Seattle Genetics to Present ADCETRIS® and ASG-5ME Data at ASCO Annual Meeting

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2012 | 12:10am CET

Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that data from two of its antibody-drug conjugate (ADC) programs, ADCETRIS (brentuximab vedotin) and ASG-5ME, will be presented at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting being held June 1-5, 2012 in Chicago, IL. A summary of the company's poster presentations is below and full abstracts can be accessed on the ASCO website at www.abstract.asco.org.

ADCETRIS

Retreatment with brentuximab vedotin in CD30-positive hematologic malignancies: a phase II study

  • Saturday, June 2; 8:00 a.m. - 1:00 p.m. Central Time (CT), with discussion from 12:00 p.m. - 1:00 p.m. CT
  • Abstract # 8027
  • Poster display in room E450b and discussion in room E354a
  • First author: Dr. Nancy L. Bartlett, Washington University, Siteman Cancer Center, St. Louis, MO

CD30 expression in non-lymphomatous malignancies

  • Monday, June 4; 8:00 a.m. - 12:00 p.m. CT
  • Abstract #3069
  • Poster presentation in S Hall A2; poster board #16C
  • First author: Dr. Jeff P. Sharman, Willamette Valley Center Institute and Research Center, Eugene, OR

Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: preliminary results from a phase II study

  • Monday, June 4; 1:15 p.m. - 5:15 p.m. CT
  • Abstract #8070
  • Poster presentation in S Hall A2; poster board #35C
  • First author: Dr. Ranjana Advani, Stanford University Medical Center, Stanford, CA

ASG-5ME

Phase 1 trial of ASG-5ME in metastatic castration-resistant prostate cancer (CRPC)

  • Monday, June 4; 8:00 a.m. - 12:00 p.m. CT, with discussion from 11:30 a.m. - 12:30 p.m. CT
  • Abstract #4568
  • Poster display in room E450a and discussion in room E Arie Crown Theater
  • First author: Dr. Michael J. Morris, Memorial Sloan Kettering Cancer Center, New York, NY

About ADCETRIS

ADCETRIS (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics' proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

Seattle Genetics and Millennium: The Takeda Oncology Company are jointly developing ADCETRIS.

Under the terms of the collaboration agreement, Seattle Genetics has U.S. and Canadian commercialization rights and the Takeda Group has rights to commercialize ADCETRIS in the rest of the world. Seattle Genetics and the Takeda Group are funding joint development costs for ADCETRIS on a 50:50 basis, except in Japan where the Takeda Group is solely responsible for development costs.

About ASG-5ME

ASG-5ME is an ADC targeting the SLC44A4 antigen and is being co-developed by Seattle Genetics and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., for the treatment of solid tumors. ASG-5ME is an ADC composed of a fully human antibody directed to SLC44A4, a solute carrier antigen family member identified by Agensys to be overexpressed in epithelial cancers, including more than 80 percent of samples derived from patients with prostate, pancreatic and gastric cancers. The antibody is attached to MMAE via an enzyme-cleavable linker using Seattle Genetics' proprietary technology. The ADC is designed to be stable in the bloodstream, but to release MMAE upon internalization into SLC44A4-expressing tumor cells, resulting in targeted cell-killing.

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The U.S. Food and Drug Administration granted accelerated approval of ADCETRIS in August 2011 for two indications. ADCETRIS is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has three other clinical-stage ADC programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys, an affiliate of Astellas, and Genmab. More information can be found at www.seattlegenetics.com.

Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SEATTLE GENETICS, INC.
01/13 SEATTLE GENETICS, INC. : SHAREHOLDER NOTICE: Lundin Law PC Announces an Investig..
01/12 SEATTLE GENETICS : New Immunoglobulins Study Findings Have Been Reported by Rese..
01/12 SEATTLE GENETICS : Initiates Phase 1 Trial of SGN-CD352A for Patients with Relap..
01/11 SEATTLE GENETICS, INC. : Lundin Law PC Announces an Investigation of Seattle Gen..
01/11 Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against..
01/11 SEATTLE GENETICS, INC. : Lundin Law PC Announces an Investigation of Seattle Gen..
01/11 Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Se..
01/09 SEATTLE GENETICS, INC. : Biotech Industry Off to a Strong Start in 2017 Latest R..
01/06 SEATTLE GENETICS NOTIFICATION : Faruqi & Faruqi, LLP Encourages Investors Who Su..
01/06 SEATTLE GENETICS : Announces Clinical Hold on Several Phase 1 Trials of Vadastux..
More news
Sector news : Biotechnology & Medical Research - NEC
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
01/04 Pharma Regulatory And Clinical Trial News Over Christmas
2016 MARKET-MAKER ODDS OF PRICE GAINS AHE : Biotech Stocks
2016 Midday Gainers / Losers
2016 HEALTHCARE - TOP GAINERS / LOSERS AS : 00 am
2016 BIOTECH FORUM DAILY DIGEST : Small Caps Rally. Spotlight On Zynerba Pharmaceutic..
Advertisement
Financials ($)
Sales 2016 420 M
EBIT 2016 -134 M
Net income 2016 -131 M
Finance 2016 461 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 18,8x
EV / Sales 2017 16,0x
Capitalization 8 369 M
More Financials
Chart SEATTLE GENETICS, INC.
Duration : Period :
Seattle Genetics, Inc. Technical Analysis Chart | SGEN | US8125781026 | 4-Traders
Full-screen chart
Technical analysis trends SEATTLE GENETICS,...
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 58,9 $
Spread / Average Target -0,32%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Clay B. Siegall Chairman, President & Chief Executive Officer
Eric L. Dobmeier Chief Operating Officer
Todd E. Simpson Chief Financial Officer
Jonathan Drachman Chief Medical Officer, EVP-Research & Development
Vaughn B. Himes Chief Technology Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SEATTLE GENETICS, INC.12.03%8 369
INCYTE CORPORATION17.43%22 182
QUINTILES IMS HOLDINGS..1.46%18 995
CELLTRION, INC.--.--%10 712
LONZA GROUP AG4.65%9 715
ALKERMES PLC-0.22%8 428
More Results